255 related articles for article (PubMed ID: 35844596)
1. Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center.
Prasad N; Bansal SB; Yadav B; Manhas N; Yadav D; Gautam S; Kushwaha R; Singh A; Bhadauria D; Yachha M; Behera MR; Kaul A
Front Immunol; 2022; 13():911738. PubMed ID: 35844596
[TBL] [Abstract][Full Text] [Related]
2. Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study.
Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
Diabetes Metab Syndr; 2022 Feb; 16(2):102424. PubMed ID: 35150961
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of SARS-CoV-2 Humoral Response Following Vaccination with ChAdOx1 nCoV-19 (Covishield™) and/or Sinopharm, BBIBP-CorV (Vero cell™).
Kamar SB; Pandey H; Shahi R; Puri S; Yadav GK; Amgain K
J Nepal Health Res Counc; 2024 Mar; 21(3):523-529. PubMed ID: 38615227
[TBL] [Abstract][Full Text] [Related]
4. Higher pro-inflammatory cytokines IL-6 and IFN-γ are associated with anti-SARS-CoV-2 spike protein-specific seroconversion in renal allograft recipients.
Yadav B; Prasad N; Kushwaha RS; Patel MR; Bhadauria D; Kaul A
Transpl Infect Dis; 2023 Oct; 25(5):e14133. PubMed ID: 37605477
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN®) and ChAdOx1 nCoV-19 (COVISHIELD™) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational study.
Asokan MS; Joan RF; Babji S; Dayma G; Nadukkandy P; Subrahmanyam V; Pandey A; Malagi G; Arya P; Mahajan V; Bhavikatti J; Pawar K; Thorat A; Shah P; Goud RB; Roy B; Rajukutty S; Immanuel S; Agarwal D; Saha S; Shivaraj A; Panikulam P; Shome R; Gulzar SE; Sharma AU; Naik A; Talashi S; Belekar M; Yadav R; Khude P; V M; Shivalingaiah S; Deshmukh U; Bhise C; Joshi M; Inbaraj LR; Chandrasingh S; Ghose A; Jamora C; Karumbati AS; Sundaramurthy V; Johnson A; Ramesh N; Chetan N; Parthiban C; Ahmed A; Rakshit S; Adiga V; D'souza G; Rale V; George CE; John J; Kawade A; Chaturvedi A; Raghunathan A; Dias M; Bhosale A; Raghu P; Shashidhara LS; Vyakarnam A; Bal V; Kang G; Mayor S
Lancet Reg Health Southeast Asia; 2024 Mar; 22():100361. PubMed ID: 38482152
[TBL] [Abstract][Full Text] [Related]
6. Humoral Immune Response of SARS-CoV-2 Infection and Anti-SARS-CoV-2 Vaccination in Renal Transplant Recipients.
Prasad N; Yadav B; Singh M; Gautam S; Bhadauria D; Patel M; Kushwaha R; Yadav D; Singh A; Yachha M; Behera M; Kaul A
Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335017
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial.
Thuluva S; Paradkar V; Gunneri S; Yerroju V; Mogulla R; Suneetha PV; Turaga K; Kyasani M; Manoharan SK; Adabala S; Sri Javvadi A; Medigeshi G; Singh J; Shaman H; Binayke A; Zaheer A; Awasthi A; Singh C; Rao A V; Basu I; Kumar KAA; Pandey AK
Hum Vaccin Immunother; 2023 Dec; 19(1):2203632. PubMed ID: 37113012
[TBL] [Abstract][Full Text] [Related]
8. Clinical Effectiveness of SARS-CoV-2 Vaccination in Renal Transplant Recipients. Antibody Levels Impact in Pneumonia and Death.
Rodríguez-Cubillo B; Moreno de la Higuera MA; Pérez-Flores I; Calvo Romero N; Aiffil AS; Arribi Vilela A; Peix B; Huertas S; Juez A; Sanchez-Fructuoso AI
Transplantation; 2022 Nov; 106(11):e476-e487. PubMed ID: 35859270
[TBL] [Abstract][Full Text] [Related]
9. A study on seroconversion following first & second doses of ChAdOx1 nCoV-19 vaccine in Central Kerala.
Varghese SM; Mateethra GC; George G; Chandran VS; John GM; Varghese LT; Mammen NK; Vinayak V
Indian J Med Res; 2022; 155(5&6):499-504. PubMed ID: 36348597
[TBL] [Abstract][Full Text] [Related]
10. Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD™ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults.
Rakshit S; Adiga V; Ahmed A; Parthiban C; Chetan Kumar N; Dwarkanath P; Shivalingaiah S; Rao S; D'Souza G; Dias M; Maguire TJA; Doores KJ; Zoodsma M; Geckin B; Dasgupta P; Babji S; van Meijgaarden KE; Joosten SA; Ottenhoff THM; Li Y; Netea MG; Stuart KD; De Rosa SC; McElrath MJ; Vyakarnam A
Front Immunol; 2022; 13():985938. PubMed ID: 36268023
[TBL] [Abstract][Full Text] [Related]
11. The humoral immune response to the BNT 162B2 vaccine in pediatrics on renal replacement therapy.
Alshami A; Bahbah H; Al Attas R; Aldokhi F; Azzam A
Pediatr Transplant; 2024 May; 28(3):e14712. PubMed ID: 38553800
[TBL] [Abstract][Full Text] [Related]
12. Seroconversion after SARS-CoV-2 vaccination is protective against severe COVID-19 disease in heart transplant recipients.
Kugler S; Vári DK; Veres DS; Király Á; Teszák T; Parázs N; Tarjányi Z; Drobni Z; Szakál-Tóth Z; Prinz G; Miheller P; Merkely B; Sax B
Immun Inflamm Dis; 2023 Nov; 11(11):e1086. PubMed ID: 38018598
[TBL] [Abstract][Full Text] [Related]
13. Pediatric population (aged 3-11 years) received primary inactivated SARS-CoV-2 vaccination prior to infection exhibiting robust humoral immune response following infected with Omicron variant: a study conducted in Beijing.
Li J; Li J; Dai S; Dang L; Wang L; Cao L; Chen X; Wang Y; Ge M; Liu W; Song Q; Xu W; Ma L
Front Immunol; 2023; 14():1269665. PubMed ID: 37828994
[TBL] [Abstract][Full Text] [Related]
14. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E
J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809
[TBL] [Abstract][Full Text] [Related]
15. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study.
Rose W; Raju R; Babji S; George A; Madhavan R; Leander Xavier JV; David Chelladurai JS; Nikitha OS; Deborah AA; Vijayakumar S; Immanuel S; John J; Rupali P; Abhilash KPP; Mohan VR; Tallapaka KB; Samuel P; Kang G
Lancet Reg Health Southeast Asia; 2023 Jan; 12():100141. PubMed ID: 36712811
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.
Arankalle V; Kulkarni-Munje A; Kulkarni R; Palkar S; Patil R; Oswal J; Lalwani S; Mishra AC
Front Immunol; 2022; 13():928501. PubMed ID: 36211366
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
19. Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients.
Biagio P; Rosa C; Nicola SM; Fabrizio S; Amerigo P; Giulia Z; Riccardo S; Riccardo V; Paolo R; Lorenzo S; Ivan G; Federico Ii Covid Team
Viruses; 2022 Sep; 14(9):. PubMed ID: 36146758
[TBL] [Abstract][Full Text] [Related]
20. A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
Stoll S; Desai S; Levit E
Mult Scler Relat Disord; 2023 Mar; 71():104574. PubMed ID: 36827874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
